Home Viamet Pharmaceuticals

Viamet Pharmaceuticals

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases

Viamet Pharmaceuticals, Inc. today announced that Chief Development Officer, Amir Tavakkol, Ph.D., Dip. Bacteriol, will present data from the Company’s VT-1161 therapeutic program in the treatment of onychomycosis, or fungal nail infection, at the 4th International Summit...